Drug Trial Radar · NCT07759934
ASK0912 Versus Polymyxin B for Injection in Adults With Hospital-Acquired or Ventilator-Associated Bacterial Pneumonia
Last checked: Nov 19, 2026Latest source record: Aug 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
60
Planned (sponsor's estimate)
Start
Mar 25, 2026
Primary completion
Oct 20, 2027
Study completion Dec 25, 2027
Sponsor
- Lead sponsor
- Jiangsu Aosaikang Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Aug 12, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a randomized, active-controlled, multicenter phase II clinical trial. The study aims to evaluate the efficacy, safety and tolerability of two different dosing regimens of ASK0912 for Injection compared with Polymyxin B Sulfate for Injection in adult patients with hospital-acquired bacterial pneumonia (HABP) or ventilator-associated bacterial pneumonia (VABP) caused by multidrug-resistant or carbapenem-resistant Gram-negative bacilli. Eligible subjects will be randomly assigned to one of three treatment groups: ASK0912 Regimen 1, ASK0912 Regimen 2, or Polymyxin B Sulfate active comparator group. Subjects will receive assigned intravenous study treatment for 7 to 14 days. The primary efficacy endpoints include clinical cure rate at the Test of Cure (TOC) visit and Day 28 all-cause mortality in the modified intent-to-treat (MITT) population. Safety assessments will be conducted throughout the study to monitor adverse events, laboratory parameters and other safety indicators.
Conditions
- Ventilator-associated Bacterial Pneumonia (VABP)
- Hospital-acquired Bacterial Pneumonia (HABP)
Interventions
ASK0912 for InjectionDrug
ASK0912 for injection administered at a dose of 0.75 mg/kg every 12 hours
ASK0912 for InjectionDrug
ASK0912 for injection administered at a dose of 0.5 mg/kg every 8 hours
Polymyxin B Sulfate for InjectionDrug
Polymyxin B Sulfate for Injection:Loading dose of 2.0-2.5 mg/kg; maintaining dose 1.25-1.5 mg/kg after 12 hours
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants Achieving Clinical Cure at Test of Cure (TOC) Visit in the Modified Intent to Treat (MITT) PopulationTime frame: Up to approximately 28 days
- Percentage of Participants With All-cause Mortality(ACM) Through Day 28 in the Modified Intent to Treat (MITT) PopulationTime frame: Up to approximately 28 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Jiangsu AOSAIKANG Pharm
Nanjing, Jiangsu, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.